Company adds Lukas Scheibler as
Chief Science and Technology Officer
STUART,
Fla., July 25, 2024 /PRNewswire/ -- Stuart
Therapeutics, a clinical-stage ophthalmic biopharmaceutical company
focused on developing therapies for the treatment of anterior
segment, refractive and posterior segment eye disorders, today
announced the addition of Lukas
Scheibler, PhD as its Chief Science and Technology
Officer.
![Stuart, Florida Stuart, Florida](https://mma.prnewswire.com/media/2469448/Stuart_Florida.jpg)
"The advancement of our pipeline of novel collagen mimetic
peptide therapeutics has increased the need for us to augment our
capabilities. We are excited to have Lukas join the Stuart
Therapeutics team as our Chief Science and Technology
Officer. He has an extensive background in pharma, and we are
particularly excited about his capabilities in retinal indications,
an area where Stuart has developed
some very exciting pre-clinical results. Lukas will work with
a strong research team that includes Brian
Del Buono, PhD, EVP R&D, and David Calkins, PhD. Dr. Calkins who has
acted as the company's Chief Science Officer, will take on the new
role as the head of our Scientific Advisory Board" said
Eric Schlumpf, Stuart's President and CEO.
"Stuart Therapeutics is developing an extremely interesting
therapeutic platform that targets diseased tissues in a novel way
compared to conventional therapeutics for ophthalmology," said Dr.
Scheibler. "The company has demonstrated the ability to build
viable development programs with a lean, effective team. I'm
pleased to be a part of this strong group, and am looking forward
to helping drive their new programs, including retinal diseases,
forward to success."
Dr. Scheibler is an R&D professional with in-depth
experience in drug development. Prior to his role at
Stuart, he was the Chief Research
Officer at Apellis Pharmaceuticals where he was responsible for
creating and managing all preclinical research projects and
advancing them into clinical development to establish proof of
concept. Prior to this, he held leading roles in Acucela, Alcon and
Novartis in research, clinical development and business
development. He holds a PhD from the University of Lausanne,
Switzerland, and has completed
postdoctoral training at Harvard Medical
School.
About Stuart Therapeutics, Inc.
Stuart Therapeutics, founded in 2017 and based in Stuart, Florida, is the leader in the
development of ECM-targeting therapeutics for disease treatment.
Its platform technology, PolyCol™, is a portfolio of
synthesized collagen mimetic peptides designed to specifically bind
to and repair disease- or injury-damaged helical collagen
structures. This activity results in both a repair of
collagen structures and a restoration of homeostatic cell
signaling, with positive effects on cell growth and proliferation
and reduction in inflammation. These effects occur rapidly in
treated tissues, and Stuart Therapeutics has extensive research
results in a variety of refractive, anterior segment and posterior
segment ophthalmic disease indications. The company's
programs include vezocolmitide, a topical drug for dry eye disease,
currently in a Phase 3 trial, and pre-clinical assets in retinal
disease and myopia. The company also has a licensing
partnership with Glaukos Corporation in glaucoma
neuroprotection. For more information,
visit www.stuarttherapeutics.com.
CONTACT: Eric Schlumpf,
President & CEO
eric@stuarttherapeutics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stuart-therapeutics-inc-announces-key-addition-to-its-executive-team-302206966.html
SOURCE Stuart Therapeutics